Emerging Approaches for the Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Therapeutic Potential of the C5a/C5aR Axis.
C5a/C5aR axis
C5aR inhibitors
CIPN
Chemotherapeutic drugs
Peripheral neuropathy
Journal
Pain and therapy
ISSN: 2193-8237
Titre abrégé: Pain Ther
Pays: New Zealand
ID NLM: 101634491
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
11
07
2022
accepted:
30
08
2022
pubmed:
14
9
2022
medline:
14
9
2022
entrez:
13
9
2022
Statut:
ppublish
Résumé
Chemotherapy-induced peripheral neuropathy (CIPN) is the most common neurologic complication of chemotherapy, resulting in symptoms like pain, sensory loss, and numbness in the hands and feet that cause lots of uneasiness in patients with cancer. They often suffer from pain so severe that it interrupts the treatment, thus invalidating the entire chemotherapy-based healing process, and significantly reducing their quality of life. In this paper, we underline the role of the complement system in CIPN, highlighting the relevance of the C5a fragment and its receptor C5aR1, whose activation is thought to be involved in triggering a cascade of events that can lead to CIPN onset. Recent experimental data showed the ability of docetaxel and paclitaxel to specifically bind and activate C5aR1, thus shining light on one of the molecular mechanisms by which taxanes may activate a cascade of events leading to neuropathy. According to these new evidence, it was possible to suggest new mechanisms underlying the pathophysiology of CIPN. Hence, the C5a/C5aR1 axis may represent a new target for CIPN treatment, and the use of C5aR1 inhibitors can be proposed as a potential new therapeutic option to manage this high unmet medical need.
Identifiants
pubmed: 36098939
doi: 10.1007/s40122-022-00431-8
pii: 10.1007/s40122-022-00431-8
pmc: PMC9469051
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1113-1136Subventions
Organisme : Ministero dello Sviluppo Economico
ID : F/090033/01-03-04/X36
Informations de copyright
© 2022. The Author(s).
Références
Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772–81.
pubmed: 28486769
pmcid: 5656281
doi: 10.1002/ana.24951
Balayssac D, Ferrier J, Descoeur J, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf. 2011;10(3):407–17.
pubmed: 21210753
doi: 10.1517/14740338.2011.543417
Zajaczkowska R, Kocot-Kepska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451.
Cioroiu C, Weimer LH. Update on chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2017;17(6):47.
pubmed: 28421360
doi: 10.1007/s11910-017-0757-7
Giorgio C, Zippoli M, Cocchiaro P, et al. Emerging role of C5 complement pathway in peripheral neuropathies: current treatments and future perspectives. Biomedicines. 2021;9(4):399.
Lees JG, Makker PG, Tonkin RS, et al. Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. Eur J Cancer. 2017;73:22–9.
pubmed: 28104535
doi: 10.1016/j.ejca.2016.12.006
Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett. 2015;596:90–107.
pubmed: 25459280
doi: 10.1016/j.neulet.2014.10.014
Burgess J, Ferdousi M, Gosal D, et al. Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol Ther. 2021;9(2):385–450.
pubmed: 34655433
pmcid: 8593126
doi: 10.1007/s40487-021-00168-y
Molassiotis A, Cheng HL, Lopez V, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019;19(1):132.
pubmed: 30736741
pmcid: 6368751
doi: 10.1186/s12885-019-5302-4
Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174.
pubmed: 28620280
pmcid: 5450696
doi: 10.3389/fnmol.2017.00174
Tian Z, Yao W. Albumin-bound paclitaxel: worthy of further study in sarcomas. Front Oncol. 2022;12: 815900.
pubmed: 35223497
pmcid: 8866444
doi: 10.3389/fonc.2022.815900
Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. Drug Des Dev Ther. 2012;6:371–84.
Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies—a growing problem for patients and health care providers. Brain Behav. 2017;7(1): e00558.
pubmed: 28127506
doi: 10.1002/brb3.558
De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S. Taxane induced neuropathy in patients affected by breast cancer: literature review. Crit Rev Oncol Hematol. 2015;96(1):34–45.
pubmed: 26004917
doi: 10.1016/j.critrevonc.2015.04.011
Salgado TM, Quinn CS, Krumbach EK, et al. Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study. Support Care Cancer. 2020;28(9):4163–72.
pubmed: 31897779
pmcid: 8261729
doi: 10.1007/s00520-019-05254-6
Gornstein EL, Schwarz TL. Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects. Exp Neurol. 2017;288:153–66.
pubmed: 27894788
doi: 10.1016/j.expneurol.2016.11.015
Liu J, Li L, Zou Y, et al. Role of microtubule dynamics in Wallerian degeneration and nerve regeneration after peripheral nerve injury. Neural Regen Res. 2022;17(3):673–81.
pubmed: 34380909
doi: 10.4103/1673-5374.320997
Klein I, Lehmann HC. Pathomechanisms of paclitaxel-induced peripheral neuropathy. Toxics. 2021;9(10):229.
Hara T, Chiba T, Abe K, et al. Effect of paclitaxel on transient receptor potential vanilloid 1 in rat dorsal root ganglion. Pain. 2013;154(6):882–9.
pubmed: 23602343
doi: 10.1016/j.pain.2013.02.023
Shim HS, Bae C, Wang J, et al. Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain. Mol Pain. 2019;15:1744806919840098.
pubmed: 30857460
pmcid: 6458664
doi: 10.1177/1744806919840098
McCormick B, Lowes DA, Colvin L, Torsney C, Galley HF. MitoVitE, a mitochondria-targeted antioxidant, limits paclitaxel-induced oxidative stress and mitochondrial damage in vitro, and paclitaxel-induced mechanical hypersensitivity in a rat pain model. Br J Anaesth. 2016;117(5):659–66.
pubmed: 27799181
doi: 10.1093/bja/aew309
Zaks-Zilberman M, Zaks TZ, Vogel SN. Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine. 2001;15(3):156–65.
pubmed: 11554785
doi: 10.1006/cyto.2001.0935
Ledeboer A, Jekich BM, Sloane EM, et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun. 2007;21(5):686–98.
pubmed: 17174526
doi: 10.1016/j.bbi.2006.10.012
Cunha TM, Barsante MM, Guerrero AT, et al. Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice. Br J Pharmacol. 2008;154(2):460–70.
pubmed: 18362895
pmcid: 2442455
doi: 10.1038/bjp.2008.94
Kim SJ, Park SM, Cho YW, et al. Changes in expression of mRNA for interleukin-8 and effects of interleukin-8 receptor inhibitor in the spinal dorsal horn in a rat model of lumbar disc herniation. Spine (Phila Pa 1976). 2011;36(25):2139–46.
doi: 10.1097/BRS.0b013e31821945a3
Verri WA Jr, Cunha TM, Parada CA, Poole S, Cunha FQ, Ferreira SH. Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol Ther. 2006;112(1):116–38.
pubmed: 16730375
doi: 10.1016/j.pharmthera.2006.04.001
Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041–53.
pubmed: 16722814
doi: 10.1517/14656566.7.8.1041
Conlin AK, Seidman AD, Bach A, et al. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2010;10(4):281–7.
pubmed: 20705560
doi: 10.3816/CBC.2010.n.036
Saif MWUS. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. JOP. 2013;14(6):686–8.
pubmed: 24216565
Goldstein D, Von Hoff DD, Moore M, et al. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: a subset analysis from a randomised phase III trial (MPACT). Eur J Cancer. 2016;52:85–91.
pubmed: 26655559
doi: 10.1016/j.ejca.2015.10.017
Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75(4):659–70.
pubmed: 25596818
pmcid: 4365177
doi: 10.1007/s00280-014-2607-5
Peng L, Bu Z, Ye X, Zhou Y, Zhao Q. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur J Cancer Care (Engl). 2017;26(5). https://doi.org/10.1111/ecc.12407 .
Schoch S, Gajewski S, Rothfuss J, Hartwig A, Koberle B. Comparative study of the mode of action of clinically approved platinum-based chemotherapeutics. Int J Mol Sci. 2020;21(18):6928.
Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer. 1988;61(11):2192–5.
pubmed: 2835140
doi: 10.1002/1097-0142(19880601)61:11<2192::AID-CNCR2820611110>3.0.CO;2-A
Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33(1):15–49.
pubmed: 16473643
doi: 10.1053/j.seminoncol.2005.12.010
Leonard GD, Wright MA, Quinn MG, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005;5:116.
pubmed: 16168057
pmcid: 1266024
doi: 10.1186/1471-2407-5-116
Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006;27(6):992–1002.
pubmed: 16797073
doi: 10.1016/j.neuro.2006.04.010
Scuteri A, Galimberti A, Maggioni D, et al. Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology. 2009;30(2):312–9.
pubmed: 19428505
doi: 10.1016/j.neuro.2009.01.003
Wahlman C, Doyle TM, Little JW, et al. Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms. Pain. 2018;159(6):1025–34.
pubmed: 29419652
pmcid: 5955834
doi: 10.1097/j.pain.0000000000001177
Miguel CA, Raggio MC, Villar MJ, Gonzalez SL, Coronel MF. Anti-allodynic and anti-inflammatory effects of 17alpha-hydroxyprogesterone caproate in oxaliplatin-induced peripheral neuropathy. J Peripher Nerv Syst. 2019;24(1):100–10.
pubmed: 30680838
doi: 10.1111/jns.12307
Cunha TM, Verri WA Jr, Silva JS, Poole S, Cunha FQ, Ferreira SH. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci USA. 2005;102(5):1755–60.
pubmed: 15665080
pmcid: 547882
doi: 10.1073/pnas.0409225102
Dhyani P, Quispe C, Sharma E, et al. Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. Cancer Cell Int. 2022;22(1):206.
pubmed: 35655306
pmcid: 9161525
doi: 10.1186/s12935-022-02624-9
Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology. 1969;19(4):367–74.
pubmed: 5813374
doi: 10.1212/WNL.19.4.367
Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol. 2000;424(4):563–76.
pubmed: 10931481
doi: 10.1002/1096-9861(20000904)424:4<563::AID-CNE1>3.0.CO;2-U
Verrills NM, Walsh BJ, Cobon GS, Hains PG, Kavallaris M. Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J Biol Chem. 2003;278(46):45082–93.
pubmed: 12949081
doi: 10.1074/jbc.M303378200
Pantani L, Zamagni E, Zannetti BA, et al. Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes. Ann Hematol. 2014;93(1):123–8.
pubmed: 23864035
doi: 10.1007/s00277-013-1828-8
Peng L, Ye X, Zhou Y, Zhang J, Zhao Q. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Support Care Cancer. 2015;23(9):2813–24.
pubmed: 25676487
doi: 10.1007/s00520-015-2648-2
Ellis RJ, Marquie-Beck J, Delaney P, et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008;64(5):566–72.
pubmed: 19067367
pmcid: 2605176
doi: 10.1002/ana.21484
Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrial-mediated disregulation of Ca
pubmed: 15867381
doi: 10.1158/0008-5472.CAN-04-3684
Stockstill K, Doyle TM, Yan X, et al. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. J Exp Med. 2018;215(5):1301–13.
pubmed: 29703731
pmcid: 5940258
doi: 10.1084/jem.20170584
Vahdat LT, Thomas ES, Roche HH, et al. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer. 2012;20(11):2661–8.
pubmed: 22382588
pmcid: 3461204
doi: 10.1007/s00520-012-1384-0
Richardson P, Hideshima T, Anderson K. Thalidomide in multiple myeloma. Biomed Pharmacother. 2002;56(3):115–28.
pubmed: 12046682
doi: 10.1016/S0753-3322(02)00168-3
Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M. Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol. 2015;33(4):113–9.
pubmed: 25399783
doi: 10.1002/hon.2149
Fernyhough P, Smith DR, Schapansky J, et al. Activation of nuclear factor-kappaB via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons. J Neurosci. 2005;25(7):1682–90.
pubmed: 15716404
pmcid: 6725919
doi: 10.1523/JNEUROSCI.3127-04.2005
Boyette-Davis JA, Hou S, Abdi S, Dougherty PM. An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy. Pain Manag. 2018;8(5):363–75.
pubmed: 30212277
pmcid: 6462837
doi: 10.2217/pmt-2018-0020
Duitama M, Vargas-Lopez V, Casas Z, Albarracin SL, Sutachan JJ, Torres YP. TRP channels role in pain associated with neurodegenerative diseases. Front Neurosci. 2020;14:782.
pubmed: 32848557
pmcid: 7417429
doi: 10.3389/fnins.2020.00782
Haraguchi K, Kawamoto A, Isami K, et al. TRPM2 contributes to inflammatory and neuropathic pain through the aggravation of pronociceptive inflammatory responses in mice. J Neurosci. 2012;32(11):3931–41.
pubmed: 22423113
pmcid: 6703465
doi: 10.1523/JNEUROSCI.4703-11.2012
Silverman HA, Chen A, Kravatz NL, Chavan SS, Chang EH. Involvement of neural transient receptor potential channels in peripheral inflammation. Front Immunol. 2020;11: 590261.
pubmed: 33193423
pmcid: 7645044
doi: 10.3389/fimmu.2020.590261
Canta A, Pozzi E, Carozzi VA. Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN). Toxics. 2015;3(2):198–223.
pubmed: 29056658
pmcid: 5634687
doi: 10.3390/toxics3020198
Basu S, Sodhi A. Increased release of interleukin-1 and tumour necrosis factor by interleukin-2-induced lymphokine-activated killer cells in the presence of cisplatin and FK-565. Immunol Cell Biol. 1992;70(Pt 1):15–24.
pubmed: 1639431
doi: 10.1038/icb.1992.3
Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3–9.
pubmed: 22537849
pmcid: 3512191
doi: 10.1016/j.cyto.2012.03.027
White FA, Sun J, Waters SM, et al. Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc Natl Acad Sci USA. 2005;102(39):14092–7.
pubmed: 16174730
pmcid: 1236537
doi: 10.1073/pnas.0503496102
Janes K, Wahlman C, Little JW, et al. Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. Brain Behav Immun. 2015;44:91–9.
pubmed: 25220279
doi: 10.1016/j.bbi.2014.08.010
Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther. 2010;126(1):56–68.
pubmed: 20117131
pmcid: 2839017
doi: 10.1016/j.pharmthera.2010.01.002
Brandolini L, d'Angelo M, Antonosante A, Allegretti M, Cimini A. Chemokine signaling in chemotherapy-induced neuropathic pain. Int J Mol Sci. 2019;20(12):2904.
Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45(2):27–37.
pubmed: 17426506
pmcid: 2785020
doi: 10.1097/AIA.0b013e318034194e
Nicolas CS, Amici M, Bortolotto ZA, et al. The role of JAK-STAT signaling within the CNS. JAKSTAT. 2013;2(1):e22925.
pubmed: 24058789
pmcid: 3670265
Uceyler N, Kafke W, Riediger N, et al. Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology. 2010;74(22):1806–13.
pubmed: 20513817
doi: 10.1212/WNL.0b013e3181e0f7b3
Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. Curr Neuropharmacol. 2019;17(2):184–96.
pubmed: 28925884
pmcid: 6343206
doi: 10.2174/1570159X15666170915143217
Bertini R, Allegretti M, Bizzarri C, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA. 2004;101(32):11791–6.
pubmed: 15282370
pmcid: 511013
doi: 10.1073/pnas.0402090101
Brandolini L, Castelli V, Aramini A, et al. DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain. Sci Rep. 2019;9(1):11729.
pubmed: 31409858
pmcid: 6692352
doi: 10.1038/s41598-019-48231-z
Griffin RS, Costigan M, Brenner GJ, et al. Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity. J Neurosci. 2007;27(32):8699–708.
pubmed: 17687047
pmcid: 6672952
doi: 10.1523/JNEUROSCI.2018-07.2007
Brandolini L, d’Angelo M, Novelli R, et al. Paclitaxel binds and activates C5aR1: a new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions. Cell Death Dis. 2022;13(5):500.
pubmed: 35614037
pmcid: 9130998
doi: 10.1038/s41419-022-04964-w
Xu J, Zhang L, Xie M, et al. Role of complement in a rat model of paclitaxel-induced peripheral neuropathy. J Immunol. 2018;200(12):4094–101.
pubmed: 29695418
doi: 10.4049/jimmunol.1701716
Meyer-Rosberg K, Kvarnstrom A, Kinnman E, Gordh T, Nordfors LO, Kristofferson A. Peripheral neuropathic pain—a multidimensional burden for patients. Eur J Pain. 2001;5(4):379–89.
pubmed: 11743704
doi: 10.1053/eujp.2001.0259
Butturini E, Carcereri de Prati A, Chiavegato G, et al. Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs. Free Radic Biol Med. 2013;65:1322–30.
pubmed: 24095958
doi: 10.1016/j.freeradbiomed.2013.09.015
Zhang H, Dougherty PM. Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. Anesthesiology. 2014;120(6):1463–75.
pubmed: 24534904
doi: 10.1097/ALN.0000000000000176
Makker PG, Duffy SS, Lees JG, et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLoS ONE. 2017;12(1):e0170814.
pubmed: 28125674
pmcid: 5268425
doi: 10.1371/journal.pone.0170814
Schlereth T. Guideline, “diagnosis and non interventional therapy of neuropathic pain” of the German Society of Neurology (deutsche Gesellschaft fur Neurologie). Neurol Res Pract. 2020;2:16.
pubmed: 33324922
pmcid: 7650069
doi: 10.1186/s42466-020-00063-3
Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73.
pubmed: 25575710
pmcid: 4493167
doi: 10.1016/S1474-4422(14)70251-0
Nagashima M, Ooshiro M, Moriyama A, et al. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Support Care Cancer. 2014;22(6):1579–84.
pubmed: 24452412
pmcid: 4008774
doi: 10.1007/s00520-014-2132-4
Kim BS, Jin JY, Kwon JH, et al. Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea. Asia Pac J Clin Oncol. 2018;14(5):e448–54.
pubmed: 29280313
doi: 10.1111/ajco.12822
Tsavaris N, Kopterides P, Kosmas C, et al. Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Med. 2008;9(8):1209–16.
pubmed: 19067834
doi: 10.1111/j.1526-4637.2007.00325.x
Magnowska M, Izycka N, Kapola-Czyz J, et al. Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy. Ginekol Pol. 2018;89(4):200–4.
pubmed: 29781075
doi: 10.5603/GP.a2018.0034
Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110(9):2110–8.
pubmed: 17853395
doi: 10.1002/cncr.23008
Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol. 2009;145(1):3–14.
pubmed: 19170681
doi: 10.1111/j.1365-2141.2008.07558.x
Kawakami K, Chiba T, Katagiri N, et al. Paclitaxel increases high voltage-dependent calcium channel current in dorsal root ganglion neurons of the rat. J Pharmacol Sci. 2012;120(3):187–95.
pubmed: 23090716
doi: 10.1254/jphs.12123FP
van den Heuvel SAS, van der Wal SEI, Smedes LA, et al. Intravenous lidocaine: old-school drug, new purpose-reduction of intractable pain in patients with chemotherapy induced peripheral neuropathy. Pain Res Manag. 2017;2017:8053474.
pubmed: 28458593
pmcid: 5387833
doi: 10.1155/2017/8053474
Egashira N, Hirakawa S, Kawashiri T, Yano T, Ikesue H, Oishi R. Mexiletine reverses oxaliplatin-induced neuropathic pain in rats. J Pharmacol Sci. 2010;112(4):473–6.
pubmed: 20308797
doi: 10.1254/jphs.10012SC
Kamei J, Nozaki C, Saitoh A. Effect of mexiletine on vincristine-induced painful neuropathy in mice. Eur J Pharmacol. 2006;536(1–2):123–7.
pubmed: 16556439
doi: 10.1016/j.ejphar.2006.02.033
Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU. Serotonin–norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol. 2009;7(4):331–6.
pubmed: 20514212
pmcid: 2811866
doi: 10.2174/157015909790031201
Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol. 1997;14(1):2–31.
pubmed: 9013357
pmcid: 7859971
doi: 10.1097/00004691-199701000-00002
Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R. Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial. Clin Drug Investig. 2020;40(3):249–57.
pubmed: 31925721
doi: 10.1007/s40261-019-00882-6
Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67.
pubmed: 23549581
pmcid: 3912515
doi: 10.1001/jama.2013.2813
Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011;29(4):421–7.
pubmed: 21189381
doi: 10.1200/JCO.2010.31.5911
Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014;32(10):997–1005.
pubmed: 24297951
doi: 10.1200/JCO.2013.52.0536
Cavaletti G, Cavalletti E, Oggioni N, et al. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology. 2000;21(3):389–93.
pubmed: 10894128
Pizzorno J. Glutathione! Integr Med (Encinitas). 2014;13(1):8–12.
Cavaletti G, Minoia C, Schieppati M, Tredici G. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys. 1994;29(4):771–6.
pubmed: 8040023
doi: 10.1016/0360-3016(94)90565-7
Leal AD, Qin R, Atherton PJ, et al. North Central Cancer Treatment Group/alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014;120(12):1890–7.
pubmed: 24619793
doi: 10.1002/cncr.28654
Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P. Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients. 2018;10(11):1564.
Vahdat L, Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res. 2001;7(5):1192–7.
pubmed: 11350883
Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel AB, Hesdorffer CS, Gooch CL. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol (R Coll Radiol). 2005;17(4):271–6.
doi: 10.1016/j.clon.2004.11.014
Gurney JG, Bass JK, Onar-Thomas A, et al. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro Oncol. 2014;16(6):848–55.
pubmed: 24414535
pmcid: 4022215
doi: 10.1093/neuonc/not241
Moore DH, Donnelly J, McGuire WP, et al. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(22):4207–13.
pubmed: 14615449
doi: 10.1200/JCO.2003.02.086
Gallegos-Castorena S, Martinez-Avalos A, Mohar-Betancourt A, Guerrero-Avendano G, Zapata-Tarres M, Medina-Sanson A. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol. 2007;24(6):403–8.
pubmed: 17710657
doi: 10.1080/08880010701451244
Duval M, Daniel SJ. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity. J Otolaryngol Head Neck Surg. 2012;41(5):309–15.
pubmed: 23092832
Guo Y, Jones D, Palmer JL, et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2014;22(5):1223–31.
pubmed: 24362907
doi: 10.1007/s00520-013-2075-1
Desideri I, Francolini G, Becherini C, et al. Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement (Opera®) for chemotherapy-induced peripheral neuropathy management, a prospective study. Med Oncol. 2017;34(3):46.
pubmed: 28205185
doi: 10.1007/s12032-017-0907-4
Maschio M, Zarabla A, Maialetti A, et al. Prevention of bortezomib-related peripheral neuropathy with docosahexaenoic acid and alpha-lipoic acid in patients with multiple myeloma: preliminary data. Integr Cancer Ther. 2018;17(4):1115–24.
pubmed: 30295079
pmcid: 6247541
doi: 10.1177/1534735418803758
Melli G, Taiana M, Camozzi F, et al. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol. 2008;214(2):276–84.
pubmed: 18809400
doi: 10.1016/j.expneurol.2008.08.013
Li K, Giustini D, Seely D. A systematic review of acupuncture for chemotherapy-induced peripheral neuropathy. Curr Oncol. 2019;26(2):e147–54.
pubmed: 31043820
pmcid: 6476456
doi: 10.3747/co.26.4261
D’Alessandro EG, Nebuloni Nagy DR, de Brito CMM, Almeida EPM, Battistella LR, Cecatto RB. Acupuncture for chemotherapy-induced peripheral neuropathy: a randomised controlled pilot study. BMJ Support Palliat Care. 2022;12(1):64–72.
pubmed: 31256014
doi: 10.1136/bmjspcare-2018-001542
Kleckner IR, Kamen C, Gewandter JS, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer. 2018;26(4):1019–28.
pubmed: 29243164
doi: 10.1007/s00520-017-4013-0
Teran-Wodzinski P, Haladay D, Vu T, et al. Assessing gait, balance, and muscle strength among breast cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): study protocol for a randomized controlled clinical trial. Trials. 2022;23(1):363.
pubmed: 35477489
pmcid: 9044705
doi: 10.1186/s13063-022-06294-w
Ma J, Kavelaars A, Dougherty PM, Heijnen CJ. Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: targeting the source. Cancer. 2018;124(11):2289–98.
pubmed: 29461625
doi: 10.1002/cncr.31248
Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. Physiol Rev. 2021;101(1):259–301.
pubmed: 32584191
doi: 10.1152/physrev.00045.2019
Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;6:257.
pubmed: 26074922
pmcid: 4443744
doi: 10.3389/fimmu.2015.00257
Kolev M, Le Friec G, Kemper C. Complement—tapping into new sites and effector systems. Nat Rev Immunol. 2014;14(12):811–20.
pubmed: 25394942
doi: 10.1038/nri3761
Sundsmo JS, Kolb WP, Muller-Eberhard HJ. Leukocyte complement: neoantigens of the membrane attack complex on the surface of human leukocytes prepared from defibrinated blood. J Immunol. 1978;120(3):850–4.
pubmed: 75929
Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I—molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
pubmed: 26082779
pmcid: 4451739
doi: 10.3389/fimmu.2015.00262
Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2007;25(11):1265–75.
pubmed: 17989689
pmcid: 2966895
doi: 10.1038/nbt1342
Shinjyo N, Stahlberg A, Dragunow M, Pekny M, Pekna M. Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem Cells. 2009;27(11):2824–32.
pubmed: 19785034
doi: 10.1002/stem.225
Reca R, Mastellos D, Majka M, et al. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood. 2003;101(10):3784–93.
pubmed: 12511407
doi: 10.1182/blood-2002-10-3233
Ignatius A, Ehrnthaller C, Brenner RE, et al. The anaphylatoxin receptor C5aR is present during fracture healing in rats and mediates osteoblast migration in vitro. J Trauma. 2011;71(4):952–60.
pubmed: 21460748
pmcid: 3186845
Ohinata K, Yoshikawa M. Food intake regulation by central complement system. Adv Exp Med Biol. 2008;632:35–46.
pubmed: 19025112
Warwick CA, Keyes AL, Woodruff TM, Usachev YM. The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain. J Biol Chem. 2021;297(3): 101085.
pubmed: 34411562
pmcid: 8446806
doi: 10.1016/j.jbc.2021.101085
Manthey HD, Woodruff TM, Taylor SM, Monk PN. Complement component 5a (C5a). Int J Biochem Cell Biol. 2009;41(11):2114–7.
pubmed: 19464229
doi: 10.1016/j.biocel.2009.04.005
Karsten CM, Laumonnier Y, Kohl J. Functional analysis of C5a effector responses in vitro and in vivo. Methods Mol Biol. 2014;1100:291–304.
pubmed: 24218268
doi: 10.1007/978-1-62703-724-2_23
Elsner J, Oppermann M, Czech W, et al. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol. 1994;24(3):518–22.
pubmed: 8125125
doi: 10.1002/eji.1830240304
O’Barr SA, Caguioa J, Gruol D, et al. Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol. 2001;166(6):4154–62.
pubmed: 11238666
doi: 10.4049/jimmunol.166.6.4154
Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33(6):479–92.
pubmed: 24161035
pmcid: 3820029
doi: 10.1016/j.semnephrol.2013.08.001
Quadros AU, Cunha TM. C5a and pain development: an old molecule, a new target. Pharmacol Res. 2016;112:58–67.
pubmed: 26855316
doi: 10.1016/j.phrs.2016.02.004
Li XX, Lee JD, Kemper C, Woodruff TM. The complement receptor C5aR2: a powerful modulator of innate and adaptive immunity. J Immunol. 2019;202(12):3339–48.
pubmed: 31160390
doi: 10.4049/jimmunol.1900371
Kemper C, Pangburn MK, Fishelson Z. Complement nomenclature 2014. Mol Immunol. 2014;61(2):56–8.
pubmed: 25081089
doi: 10.1016/j.molimm.2014.07.004
Nabizadeh JA, Manthey HD, Panagides N, et al. C5a receptors C5aR1 and C5aR2 mediate opposing pathologies in a mouse model of melanoma. FASEB J. 2019;33(10):11060–71.
pubmed: 31298935
doi: 10.1096/fj.201800980RR
Chenoweth DE, Hugli TE. Human C5a and C5a analogs as probes of the neutrophil C5a receptor. Mol Immunol. 1980;17(2):151–61.
pubmed: 6248769
doi: 10.1016/0161-5890(80)90067-X
Gerard NP, Hodges MK, Drazen JM, Weller PF, Gerard C. Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J Biol Chem. 1989;264(3):1760–6.
pubmed: 2912983
doi: 10.1016/S0021-9258(18)94252-3
Werfel T, Oppermann M, Schulze M, Krieger G, Weber M, Gotze O. Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood. 1992;79(1):152–60.
pubmed: 1345807
doi: 10.1182/blood.V79.1.152.152
Laudes IJ, Chu JC, Huber-Lang M, et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol. 2002;169(10):5962–70.
pubmed: 12421982
doi: 10.4049/jimmunol.169.10.5962
Gasque P, Chan P, Fontaine M, et al. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol. 1995;155(10):4882–9.
pubmed: 7594492
Lacy M, Jones J, Whittemore SR, Haviland DL, Wetsel RA, Barnum SR. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. J Neuroimmunol. 1995;61(1):71–8.
pubmed: 7560015
doi: 10.1016/0165-5728(95)00075-D
Nataf S, Levison SW, Barnum SR. Expression of the anaphylatoxin C5a receptor in the oligodendrocyte lineage. Brain Res. 2001;894(2):321–6.
pubmed: 11251209
doi: 10.1016/S0006-8993(01)02003-0
Zwirner J, Gotze O, Begemann G, Kapp A, Kirchhoff K, Werfel T. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology. 1999;97(1):166–72.
pubmed: 10447728
pmcid: 2326815
doi: 10.1046/j.1365-2567.1999.00764.x
Coulthard LG, Hawksworth OA, Li R, et al. Complement C5aR1 signaling promotes polarization and proliferation of embryonic neural progenitor cells through PKCzeta. J Neurosci. 2017;37(22):5395–407.
pubmed: 28455369
pmcid: 6596536
doi: 10.1523/JNEUROSCI.0525-17.2017
Yuan G, Wei J, Zhou J, Hu H, Tang Z, Zhang G. Expression of C5aR (CD88) of synoviocytes isolated from patients with rheumatoid arthritis and osteoarthritis. Chin Med J (Engl). 2003;116(9):1408–12.
Schulze-Tanzil G, Kohl B, El Sayed K, et al. Anaphylatoxin receptors and complement regulatory proteins in human articular and non-articular chondrocytes: interrelation with cytokines. Cell Tissue Res. 2012;350(3):465–75.
pubmed: 23053049
doi: 10.1007/s00441-012-1497-2
Allegretti M, Moriconi A, Beccari AR, et al. Targeting C5a: recent advances in drug discovery. Curr Med Chem. 2005;12(2):217–36.
pubmed: 15638737
doi: 10.2174/0929867053363379
Woodruff TM, Crane JW, Proctor LM, et al. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 2006;20(9):1407–17.
pubmed: 16816116
doi: 10.1096/fj.05-5814com
Okroj M, Heinegard D, Holmdahl R, Blom AM. Rheumatoid arthritis and the complement system. Ann Med. 2007;39(7):517–30.
pubmed: 17852027
doi: 10.1080/07853890701477546
Charchaflieh J, Wei J, Labaze G, et al. The role of complement system in septic shock. Clin Dev Immunol. 2012;2012: 407324.
pubmed: 23049598
pmcid: 3459296
doi: 10.1155/2012/407324
Ballanti E, Perricone C, Greco E, et al. Complement and autoimmunity. Immunol Res. 2013;56(2–3):477–91.
pubmed: 23615835
doi: 10.1007/s12026-013-8422-y
Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol. 2004;4(2):133–42.
pubmed: 15040586
doi: 10.1038/nri1269
Baron R. Mechanisms of disease: neuropathic pain—a clinical perspective. Nat Clin Pract Neurol. 2006;2(2):95–106.
pubmed: 16932531
doi: 10.1038/ncpneuro0113
Jang JH, Clark DJ, Li X, Yorek MS, Usachev YM, Brennan TJ. Nociceptive sensitization by complement C5a and C3a in mouse. Pain. 2010;148(2):343–52.
pubmed: 20031321
doi: 10.1016/j.pain.2009.11.021
Miller RJ, Jung H, Bhangoo SK, White FA. Cytokine and chemokine regulation of sensory neuron function. Handb Exp Pharmacol. 2009;194:417–49.
doi: 10.1007/978-3-540-79090-7_12
Perkins NM, Tracey DJ. Hyperalgesia due to nerve injury: role of neutrophils. Neuroscience. 2000;101(3):745–57.
pubmed: 11113323
doi: 10.1016/S0306-4522(00)00396-1
Dailey AT, Avellino AM, Benthem L, Silver J, Kliot M. Complement depletion reduces macrophage infiltration and activation during Wallerian degeneration and axonal regeneration. J Neurosci. 1998;18(17):6713–22.
pubmed: 9712643
pmcid: 6792968
doi: 10.1523/JNEUROSCI.18-17-06713.1998
Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007;10(11):1361–8.
pubmed: 17965656
doi: 10.1038/nn1992
Ting E, Guerrero AT, Cunha TM, et al. Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain. Br J Pharmacol. 2008;153(5):1043–53.
pubmed: 18084313
doi: 10.1038/sj.bjp.0707640
Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5–C5a receptor axis. Mol Immunol. 2011;48(14):1631–42.
pubmed: 21549429
doi: 10.1016/j.molimm.2011.04.014
Harris CL. Expanding horizons in complement drug discovery: challenges and emerging strategies. Semin Immunopathol. 2018;40(1):125–40.
pubmed: 28986638
doi: 10.1007/s00281-017-0655-8
Allegretti M, Bertini R, Bizzarri C, Beccari A, Mantovani A, Locati M. Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls. Trends Pharmacol Sci. 2008;29(6):280–6.
pubmed: 18423629
doi: 10.1016/j.tips.2008.03.005
Liu H, Kim HR, Deepak R, et al. Orthosteric and allosteric action of the C5a receptor antagonists. Nat Struct Mol Biol. 2018;25(6):472–81.
pubmed: 29867214
doi: 10.1038/s41594-018-0067-z
Merkel PA, Jayne DR, Wang C, Hillson J, Bekker P. Evaluation of the safety and efficacy of avacopan, a C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide/azathioprine: protocol for a randomized, double-blind, active-controlled, phase 3 trial. JMIR Res Protoc. 2020;9(4): e16664.
pubmed: 32088663
pmcid: 7175182
doi: 10.2196/16664
Robson J, Doll H, Suppiah R, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;54(3):471–81.
doi: 10.1093/rheumatology/keu366
Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756–67.
pubmed: 28400446
pmcid: 5576933
doi: 10.1681/ASN.2016111179
Llaudo I, Fribourg M, Medof ME, Conde P, Ochando J, Heeger PS. C5aR1 regulates migration of suppressive myeloid cells required for costimulatory blockade-induced murine allograft survival. Am J Transplant. 2019;19(3):633–45.
pubmed: 30106232
doi: 10.1111/ajt.15072
Ghouse SM, Vadrevu SK, Manne S, et al. Therapeutic targeting of vasculature in the premetastatic and metastatic niches reduces lung metastasis. J Immunol. 2020;204(4):990–1000.
pubmed: 31900334
doi: 10.4049/jimmunol.1901208
Dumitru AC, Deepak R, Liu H, et al. Submolecular probing of the complement C5a receptor-ligand binding reveals a cooperative two-site binding mechanism. Commun Biol. 2020;3(1):786.
pubmed: 33339958
pmcid: 7749166
doi: 10.1038/s42003-020-01518-8
Kumar V, Lee JD, Clark RJ, Noakes PG, Taylor SM, Woodruff TM. Preclinical pharmacokinetics of complement C5a receptor antagonists PMX53 and PMX205 in mice. ACS Omega. 2020;5(5):2345–54.
pubmed: 32064396
pmcid: 7017397
doi: 10.1021/acsomega.9b03735
Kohl J. Drug evaluation: the C5a receptor antagonist PMX-53. Curr Opin Mol Ther. 2006;8(6):529–38.
pubmed: 17243489
Fredslund F, Laursen NS, Roversi P, et al. Structure of and influence of a tick complement inhibitor on human complement component 5. Nat Immunol. 2008;9(7):753–60.
pubmed: 18536718
doi: 10.1038/ni.1625
Moriconi A, Cunha TM, Souza GR, et al. Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief. Proc Natl Acad Sci USA. 2014;111(47):16937–42.
pubmed: 25385614
pmcid: 4250151
doi: 10.1073/pnas.1417365111
Brandolini L, Grannonico M, Bianchini G, et al. The novel C5aR antagonist DF3016A protects neurons against ischemic neuroinflammatory injury. Neurotox Res. 2019;36(1):163–74.
pubmed: 30953275
pmcid: 6570783
doi: 10.1007/s12640-019-00026-w
Ding P, Li L, Li L, et al. C5aR1 is a master regulator in colorectal tumorigenesis via immune modulation. Theranostics. 2020;10(19):8619–32.
pubmed: 32754267
pmcid: 7392014
doi: 10.7150/thno.45058
Ajona D, Ortiz-Espinosa S, Moreno H, et al. A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis. Cancer Discov. 2017;7(7):694–703.
pubmed: 28288993
doi: 10.1158/2159-8290.CD-16-1184
Schott AF, Goldstein LJ, Cristofanilli M, et al. Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2-negative metastatic breast cancer. Clin Cancer Res. 2017;23(18):5358–65.
pubmed: 28539464
pmcid: 5600824
doi: 10.1158/1078-0432.CCR-16-2748
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237–51.
pubmed: 22437869
pmcid: 3967236
doi: 10.1038/nrc3237
Nakajima TE, Kadowaki S, Minashi K, et al. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Clin Cancer Res. 2021;27(4):1029–36.
pubmed: 33262133
doi: 10.1158/1078-0432.CCR-20-3559